Ausgabe 3/2019
Inhalt (9 Artikel)
Determining Value in Health Technology Assessment: Stay the Course or Tack Away?
J. Jaime Caro, John E. Brazier, Jonathan Karnon, Peter Kolominsky-Rabas, Alistair J. McGuire, Erik Nord, Michael Schlander
Economic Burden of Renal Cell Carcinoma—Part I: An Updated Review
Chun-Ru Chien, Daniel M. Geynisman, Bumyang Kim, Ying Xu, Ya-Chen Tina Shih
Ibrutinib for Treating Relapsed or Refractory Mantle Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Paul Tappenden, Emma Simpson, Jean Hamilton, Daniel Pollard, Mark Clowes, Eva Kaltenthaler, David Meiklejohn, Nick Morley
Cladribine Tablets for the First-Line Treatment of Relapsing-Remitting Multiple Sclerosis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Tosin Lambe, Rui Duarte, James Mahon, Sarah Nevitt, Janette Greenhalgh, Angela Boland, Sophie Beale, Eleanor Kotas, Joanne McEntee, Ian Pomeroy
Evaluating Cost-Effectiveness Models for Pharmacologic Interventions in Adults with Heart Failure: A Systematic Literature Review
Gian Luca Di Tanna, Anna Bychenkova, Frank O’Neill, Heidi S. Wirtz, Paul Miller, Briain Ó Hartaigh, Gary Globe
Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States
Holly Guy, Lydia Walder, Mark Fisher
Measuring Public Preferences for Health Outcomes and Expenditures in a Context of Healthcare Resource Re-Allocation
Nicolas Krucien, Nathalie Pelletier-Fleury, Amiram Gafni
Opioid Use is Associated with Higher Severity-Adjusted Episode Costs in Patients with Conservatively Managed Degenerative Joint Disease of the Back and Neck
Brent A. Metfessel, Michelle D. Mentel, Amy Phanel, Mary Ann Dimartino, Mureen Allen, Samuel Ho
Cost Effectiveness of Inhaled Mannitol (Bronchitol®) in Patients with Cystic Fibrosis
Emma Warren, Kristen Morgan, Toby J. Toward, Matthias Schwenkglenks, Joanna Leadbetter